MedTrace Logo

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC

NCT05464082 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-02-20

No results posted yet for this study

Summary

This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.

Conditions

  • Breast Cancer Recurrent

Interventions

OTHER

Functional Precision Oncology

Patient derived models (PDMs), comprising patient derived xenografts (PDXs) and organoids (PDO and PDxO),

Sponsors & Collaborators

Principal Investigators

  • Christos Vaklavas, MD · Huntsman Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-06
Primary Completion
2026-09-30
Completion
2028-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05464082 on ClinicalTrials.gov